Bausch & Lomb Corp
BLCO- Exchange
- NYSE
- Industry
- Ophthalmic Goods
- SEC CIK
- 0001860742
In the last 90 days, Bausch & Lomb Corp insiders filed 0 open-market purchases and 1 sale; 99 institutions reported holding it in 13F filings for Q2 2026, worth $638.7M in total; 3 superinvestors hold it, including Icahn Capital and Oaktree Capital.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $360.0M (7.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 |
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B |
| Research and development | $371.0M | $343.0M | $324.0M | $307.0M |
| Selling, general and administrative | $2.23B | $2.08B | $1.74B | $1.48B |
| Operating income | $113.0M | $162.0M | $130.0M | $207.0M |
| Interest expense | $421.0M | $399.0M | $283.0M | $146.0M |
| Income tax | $35.0M | $71.0M | $82.0M | $58.0M |
| Net income | -$360.0M | -$317.0M | -$260.0M | $6.00M |
| EPS, basic | $-1.02 | $-0.90 | $-0.74 | $0.02 |
| EPS, diluted | $-1.02 | $-0.90 | $-0.74 | $0.02 |
| Weighted shares, basic | 353.8M | 351.8M | 350.5M | 350.0M |
| Weighted shares, diluted | 353.8M | 351.8M | 350.5M | 350.2M |
| Margins and growth | ||||
| Operating margin | 2.2% | 3.4% | 3.1% | 5.5% |
| Net margin | -7.1% | -6.6% | -6.3% | 0.2% |
| Revenue growth, year over year | +6.5% | +15.6% | +10.0% | – |
| Net income growth, year over year | – | – | −4,433.3% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 |
| Cash and equivalents | $383.0M | $305.0M | $331.0M | $354.0M |
| Accounts receivable | $1.22B | $1.03B | $839.0M | $724.0M |
| Inventory | $976.0M | $1.04B | $1.03B | $628.0M |
| Total current assets | $2.98B | $2.79B | $2.74B | $2.14B |
| Property, plant and equipment | $1.76B | $1.49B | $1.39B | $1.30B |
| Goodwill | $4.76B | $4.52B | $4.58B | $4.51B |
| Intangible assets | $3.28B | $3.49B | $3.59B | $2.06B |
| Total assets | $14.0B | $13.5B | $13.4B | $11.1B |
| Accounts payable | $388.0M | $389.0M | $522.0M | $370.0M |
| Short-term debt | $28.0M | $40.0M | $30.0M | $25.0M |
| Total current liabilities | $1.92B | $1.74B | $1.58B | $1.30B |
| Long-term debt | $5.02B | $4.74B | $4.53B | $2.41B |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B |
| Shareholders' equity | $6.52B | $6.54B | $6.92B | $7.10B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 18, 2026 | Feb 19, 2025 | Feb 21, 2024 | Feb 22, 2023 |
| Operating cash flow | $283.0M | $232.0M | -$17.0M | $345.0M |
| Capital expenditures | $349.0M | $291.0M | $181.0M | $175.0M |
| Free cash flow | -$66.0M | -$59.0M | -$198.0M | $170.0M |
| Depreciation and amortization | $421.0M | $436.0M | $382.0M | $379.0M |
| Stock-based compensation | $149.0M | $92.0M | $74.0M | $62.0M |
| Investing cash flow | -$455.0M | -$412.0M | -$2.11B | -$215.0M |
| Financing cash flow | $225.0M | $178.0M | $2.08B | $81.0M |
| Net change in cash | $81.0M | -$18.0M | -$46.0M | $203.0M |
| Ratio | ||||
| Stock-based compensation, % of revenue | 2.9% | 1.9% | 1.8% | 1.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 21, 2026 | 357.5M | +0.9% | SEC |
| Jul 22, 2026 | 357.2M | +0.9% | SEC |
| Apr 22, 2026 | 356.5M | +0.9% | SEC |
| Feb 11, 2026 | 354.3M | +0.5% | SEC |
| Oct 22, 2025 | 354.2M | +0.6% | SEC |
| Jul 23, 2025 | 353.9M | +0.6% | SEC |
| Apr 23, 2025 | 353.4M | +0.5% | SEC |
| Feb 12, 2025 | 352.5M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.